Concepedia

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

Luana Calabrò, Aldo Morra, Ester Fonsatti, Ornella Cutaia, Carolina Fazio, Diego Annesi, M. Lenoci, Giovanni Amato, Riccardo Danielli, Maresa Altomonte,

The Lancet Respiratory Medicine · 2015 · 204 citations · 15 references

DOI

Concepts

References

15

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok, Axel Hoos, Steven O’Day et al. · Clinical Cancer Research · 2009 · 3.2K citations

, , +17

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3.1K citations

, , +13

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Thomas J. Lynch, Igor Bondarenko, Alexander Luft et al. · Journal of Clinical Oncology · 2012 · 1K citations · Full text

, , +17

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

Antoni Ribas, Richard Kefford, Margaret Marshall et al. · Journal of Clinical Oncology · 2013 · 815 citations · Full text

, , +15

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

Michael Byrne, Anna K. Nowak · Annals of Oncology · 2004 · 646 citations · Full text

, , +9